vs
Prestige Consumer Healthcare Inc.（PBH）とBRC Group Holdings, Inc.（RILY）の財務データ比較。上の社名をクリックして会社を切り替えられます
Prestige Consumer Healthcare Inc.の直近四半期売上が大きい（$283.4M vs $188.3M、BRC Group Holdings, Inc.の約1.5倍）。BRC Group Holdings, Inc.の純利益率が高く（47.9% vs 16.5%、差は31.5%）。Prestige Consumer Healthcare Inc.の前年同期比売上増加率が高い（-2.4% vs -21.9%）。過去8四半期でPrestige Consumer Healthcare Inc.の売上複合成長率が高い（1.2% vs -15.4%）
プレステージ・コンシューマー・ヘルスケア社はアメリカの企業で、一般用医薬品のヘルスケア製品および家庭用洗浄製品の販売・流通を手がけています。1996年にMedtech Products社、Prestige Brands International社、Spic and Span社の合併により設立され、本社はニューヨーク州タリータウン、バージニア州リンチバーグに製造工場を構えています。
PBH vs RILY — 直接比較
売上が大きい
PBH
1.5倍大きい
$188.3M
売上成長率が高い
PBH
+19.5%の差
-21.9%
純利益率が高い
RILY
純利益率が31.5%高い
16.5%
2年売上CAGRが高い
PBH
2年複合成長率
-15.4%
損益計算書 — Q3 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $283.4M | $188.3M |
| 純利益 | $46.7M | $90.3M |
| 粗利率 | 55.5% | 79.5% |
| 営業利益率 | 29.1% | 32.3% |
| 純利益率 | 16.5% | 47.9% |
| 売上前年比 | -2.4% | -21.9% |
| 純利益前年比 | -23.5% | 1710.8% |
| EPS（希薄化後） | $0.97 | $2.78 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上PBHRILY
| Q4 25 | $283.4M | $188.3M | ||
| Q3 25 | $274.1M | $215.3M | ||
| Q2 25 | $249.5M | $188.2M | ||
| Q1 25 | $296.5M | $197.2M | ||
| Q4 24 | $290.3M | $241.0M | ||
| Q3 24 | $283.8M | $225.5M | ||
| Q2 24 | $267.1M | $256.0M | ||
| Q1 24 | $277.0M | $263.4M |
純利益PBHRILY
| Q4 25 | $46.7M | $90.3M | ||
| Q3 25 | $42.2M | $91.1M | ||
| Q2 25 | $47.5M | $139.5M | ||
| Q1 25 | $50.1M | $-10.0M | ||
| Q4 24 | $61.0M | $-5.6M | ||
| Q3 24 | $54.4M | $-284.4M | ||
| Q2 24 | $49.1M | $-433.6M | ||
| Q1 24 | $49.5M | $-49.2M |
粗利率PBHRILY
| Q4 25 | 55.5% | 79.5% | ||
| Q3 25 | 55.3% | 83.7% | ||
| Q2 25 | 56.2% | 81.3% | ||
| Q1 25 | 57.3% | 81.4% | ||
| Q4 24 | 55.5% | 79.8% | ||
| Q3 24 | 55.5% | 82.1% | ||
| Q2 24 | 54.7% | 84.5% | ||
| Q1 24 | 54.8% | 85.3% |
営業利益率PBHRILY
| Q4 25 | 29.1% | 32.3% | ||
| Q3 25 | 29.1% | 30.4% | ||
| Q2 25 | 28.8% | 5.7% | ||
| Q1 25 | 29.8% | -31.2% | ||
| Q4 24 | 31.7% | -69.2% | ||
| Q3 24 | 29.7% | -36.4% | ||
| Q2 24 | 27.0% | -90.8% | ||
| Q1 24 | 29.7% | -6.1% |
純利益率PBHRILY
| Q4 25 | 16.5% | 47.9% | ||
| Q3 25 | 15.4% | 42.3% | ||
| Q2 25 | 19.0% | 74.1% | ||
| Q1 25 | 16.9% | -5.1% | ||
| Q4 24 | 21.0% | -2.3% | ||
| Q3 24 | 19.2% | -126.1% | ||
| Q2 24 | 18.4% | -169.4% | ||
| Q1 24 | 17.9% | -18.7% |
EPS（希薄化後）PBHRILY
| Q4 25 | $0.97 | $2.78 | ||
| Q3 25 | $0.86 | $2.91 | ||
| Q2 25 | $0.95 | $4.50 | ||
| Q1 25 | $1.00 | $-0.39 | ||
| Q4 24 | $1.22 | $-0.01 | ||
| Q3 24 | $1.09 | $-9.39 | ||
| Q2 24 | $0.98 | $-14.35 | ||
| Q1 24 | $0.98 | $-1.71 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $62.4M | $226.6M |
| 総負債低いほど良い | $1.0B | $1.4B |
| 株主資本純資産 | $1.8B | $-171.5M |
| 総資産 | $3.5B | $1.7B |
| 負債/資本比率低いほどレバレッジが低い | 0.56× | — |
8四半期トレンド — 暦四半期で整列
現金・短期投資PBHRILY
| Q4 25 | $62.4M | $226.6M | ||
| Q3 25 | $119.1M | $184.2M | ||
| Q2 25 | $139.5M | $267.4M | ||
| Q1 25 | $97.9M | $138.3M | ||
| Q4 24 | $50.9M | $146.9M | ||
| Q3 24 | $51.5M | $159.2M | ||
| Q2 24 | $34.3M | $236.9M | ||
| Q1 24 | $46.5M | $190.7M |
総負債PBHRILY
| Q4 25 | $1.0B | $1.4B | ||
| Q3 25 | $993.1M | $1.3B | ||
| Q2 25 | $992.7M | $1.3B | ||
| Q1 25 | $992.4M | $1.4B | ||
| Q4 24 | $992.0M | $1.5B | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — |
株主資本PBHRILY
| Q4 25 | $1.8B | $-171.5M | ||
| Q3 25 | $1.8B | $-260.5M | ||
| Q2 25 | $1.9B | $-351.7M | ||
| Q1 25 | $1.8B | $-496.8M | ||
| Q4 24 | $1.8B | $-488.2M | ||
| Q3 24 | $1.7B | $-497.6M | ||
| Q2 24 | $1.7B | $-218.3M | ||
| Q1 24 | $1.7B | $228.4M |
総資産PBHRILY
| Q4 25 | $3.5B | $1.7B | ||
| Q3 25 | $3.4B | $1.7B | ||
| Q2 25 | $3.4B | $1.5B | ||
| Q1 25 | $3.4B | $1.5B | ||
| Q4 24 | $3.3B | $1.8B | ||
| Q3 24 | $3.3B | $2.2B | ||
| Q2 24 | $3.3B | $3.2B | ||
| Q1 24 | $3.3B | $5.0B |
負債/資本比率PBHRILY
| Q4 25 | 0.56× | — | ||
| Q3 25 | 0.54× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.54× | — | ||
| Q4 24 | 0.55× | — | ||
| Q3 24 | 0.61× | — | ||
| Q2 24 | 0.65× | — | ||
| Q1 24 | 0.68× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $78.3M | $26.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $75.3M | — |
| FCFマージンFCF / 売上 | 26.6% | — |
| 設備投資強度設備投資 / 売上 | 1.1% | — |
| キャッシュ転換率営業CF / 純利益 | 1.68× | 0.29× |
| 直近12ヶ月FCF直近4四半期 | $267.2M | — |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローPBHRILY
| Q4 25 | $78.3M | $26.2M | ||
| Q3 25 | $57.5M | $-60.6M | ||
| Q2 25 | $79.0M | $-25.6M | ||
| Q1 25 | $61.8M | $184.0K | ||
| Q4 24 | $65.1M | $-2.7M | ||
| Q3 24 | $69.8M | $19.5M | ||
| Q2 24 | $54.8M | $111.5M | ||
| Q1 24 | $66.9M | $135.4M |
フリーキャッシュフローPBHRILY
| Q4 25 | $75.3M | — | ||
| Q3 25 | $55.4M | — | ||
| Q2 25 | $78.2M | — | ||
| Q1 25 | $58.4M | — | ||
| Q4 24 | $63.5M | — | ||
| Q3 24 | $67.8M | — | ||
| Q2 24 | $53.6M | — | ||
| Q1 24 | $63.8M | — |
FCFマージンPBHRILY
| Q4 25 | 26.6% | — | ||
| Q3 25 | 20.2% | — | ||
| Q2 25 | 31.3% | — | ||
| Q1 25 | 19.7% | — | ||
| Q4 24 | 21.9% | — | ||
| Q3 24 | 23.9% | — | ||
| Q2 24 | 20.1% | — | ||
| Q1 24 | 23.0% | — |
設備投資強度PBHRILY
| Q4 25 | 1.1% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 1.1% | — |
キャッシュ転換率PBHRILY
| Q4 25 | 1.68× | 0.29× | ||
| Q3 25 | 1.36× | -0.66× | ||
| Q2 25 | 1.66× | -0.18× | ||
| Q1 25 | 1.23× | — | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | 1.28× | — | ||
| Q2 24 | 1.12× | — | ||
| Q1 24 | 1.35× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
